1 / 12

Chemistry 910 Practical Medicinal Chemistry

Chemistry 910 Practical Medicinal Chemistry. Dr John Carran Queen’s University Department of Chemistry. Background. In conjunction with Dale Cameron To develop a course to teach the fundamentals of medicinal chemistry and then to apply them Lecture component Practical component.

Angelica
Download Presentation

Chemistry 910 Practical Medicinal Chemistry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemistry 910Practical Medicinal Chemistry Dr John Carran Queen’s University Department of Chemistry

  2. Background • In conjunction with Dale Cameron • To develop a course to teach the fundamentals of medicinal chemistry and then to apply them • Lecture component • Practical component

  3. Lecture component • Where do drugs act • How do drugs bind • How are drugs metabolised/consequences • How are drugs administered/consequences • How are drugs tested • SAR/QSAR • Molecular modeling (Mike Kuiper, Melbourne, Australia) • Lead compound generation/drug design • Chemistry and improving activity/drug design • Business/intellectual property (Angela Lyon, Parteq, Queen’s University) • Process/scale up • Clinical trials • Case studies

  4. Practical component • Aim: To mimic an industrial lead compound selection process. Opiate analgesics. • Each week for 5 weeks a series of compounds with associated data is released. • Each “company” must select one compound to progress in their pipeline to lead compound designation • Each company must rationalise their selection process to a Medicinal Chemistry mentor.

  5. Mentors • Dale Cameron - Migenix Corp • Jack Bikker –Wyeth Research • Harold Mastalertz – BMS • Sheldon Hiebert – BMS • Sheldon Crane – Merck Dinesh Vyas Rick Friesen

  6. Video conferencing • One per week, weeks 7-11 • Skype or VSee (Free!) • Each “company” has 30 minutes • Questions from mentor on selection process / red herrings • Teaching component • Evaluations on “company” and individual members returned to me

  7. “Red Herrings”

  8. Sample compound information

  9. Course breakdown • Take home assignment (mechanism question in synthesis of Artemisinin) and “midterm” week 6 (handout) (50%) • Videoconferencing assignments (5), weeks 7-11 (25% total) • Professional project report week 9 (5%) • Final poster presentation week 12 (20%)

  10. Aims of marked component • Midterm exam- examines lecture component material • Videoconferencing – communication, rationale, comprehension • Report – communication, comprehension • Poster presentation – future work, innovation

  11. Current enrollment • Six students • 3 companies (teams) of two students • 5 chemists, 1 pharmacologist • Ideal enrollment 12+ of mixed groups (chemist + pharmacologist + biochemist)

  12. Acknowledgements • QCIC • Dale Cameron, Dinesh Vyas, Rick Friesen, Jack Bikker • Harold Mastalertz, Sheldon Hiebert, Sheldon Crane • Angela Lyon, Michael Kuiper • Caitlin Latimer (SWEP program, Queen’s University)

More Related